Last reviewed · How we verify
NCT03430635
Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma
trial testing Hepatectomy in Hepatocellular Carcinoma in 40 participants. Completed in 31 January 2016.
31 December 2015
Quick facts
| Lead sponsor | Humanitas Clinical and Research Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 January 2010 |
| Primary completion | 31 December 2015 |
| Estimated completion | 31 January 2016 |
Drugs / interventions tested
- Hepatectomy
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Humanitas Clinical and Research Center
Who can join
18 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
¹¹C-choline positron emission tomography/computed tomography (PET/CT) has been used in patients with some types of solid cancers, but few data are available in patients undergoing hepatectomy for hepatocellular carcinoma (HCC). The aim of this study was to analyze the prognostic value of metabolic imaging data by using ¹¹C-choline PET/CT in patients with HCC before hepatectomy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prognostic Value of Metabolic Imaging Data of <sup>11</sup>C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma.
Donadon M, Lopci E, Galvanin J, Giudici S, et al · · 2021 · cited 5× · PMID 33530520 · DOI 10.3390/cancers13030472
Verify or expand the search:
- PubMed search for NCT03430635
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hepatectomy
Trials testing the same drug.
- NCT06559761 — Image Driven Hepatocellular Carcinoma Invasiveness Evaluation Research · recruiting
- NCT05471674 — Neoadjuvant Anti-PD1 in HCC · Phase 2 · completed
- NCT03844750 — Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases · Phase 2 · terminated
- NCT04705194 — Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging · unknown
- NCT03614546 — Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma · NA · unknown
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Humanitas Clinical and Research Center trials
Trials by the same sponsor.
- NCT07161297 — Remimazolam for Colonoscopy in IBD Patients · Phase 4 · not yet recruiting
- NCT04934943 — "Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools" · not yet recruiting
- NCT06394947 — Fluid Challenge in Intensive Care The FENICE II Study · completed
- NCT06627907 — Hemodynamic Response to the End-expiratory Occlusion Test to Titrate Fluid Challenge in Operating Room. · not yet recruiting
- NCT06099171 — Therapy With Paravertebral Oxygen-ozone Injections and Topical Cannabidiol and β-Caryophyllene Patch in Neck Pain · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03430635 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Humanitas Clinical and Research Center
- Last refreshed: 13 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430635.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing